Related Experiment Video
Updated: Aug 17, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Hepatic injury in a patient taking rosiglitazone
Stacy B Menees1, Michelle A Anderson, Stephen W Chensue
1Veterans Affairs Medical Center and University of Michigan Medical School Ann Arbor, MI 48105-2300, USA.
Abstract:
We describe a 52-year-old man with type 2 diabetes mellitus who developed cholestatic hepatitis in association with rosiglitazone use. Liver biopsy findings included dilated canaliculi, inspissated bile, intrahepatocellular bile pigment deposits, and enlarged xanthomatous Kupffer cells. The form of liver injury reported in this case differs markedly from those reported previously for rosiglitazone.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetic Retinopathy
Dipeptidyl Peptidase 4 Inhibitors
Hyperglycemia
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...